An Open-label, Safety Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Next Previous
Trial Profile

An Open-label, Safety Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics

    • Most Recent Events

    • 15 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
    • 15 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2018.
    • 21 Jul 2016 Planned End Date changed from 1 Dec 2014 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top